Alliance Awards Support Innovative Researchers

The Alliance for Clinical Trials in Oncology Foundation invites applications for grants to support research activities of oncology junior faculty at Alliance institutions.

2012 Alliance Clinical Scholar Award
2012 Alliance Investigator Award

The Clinical Scholar Award and Investigator Award support research that assesses interventions in cancer patients and/or examines biological specimens obtained from cancer patients. These awards are exclusively for oncology junior faculty (ranked below Associate Professor) at Alliance institutions, who have completed training in an oncology clinical specialty (e.g., medical, surgical, radiation, gynecologic, etc.). Award submissions are limited to research related to the research agenda of the Alliance scientific committees.

Clinical Scholar award recipients must be within four to six years of a faculty appointment at the time of the award and will receive up to $40,000 plus 10 percent overhead each year for two years. Investigator award recipients must be within one to three years of a faculty appointment at the time of the award and will receive up to $30,000 plus 10 percent overhead for one year. Each award is non-renewable. Projects supported by other non-institutional funds are not eligible.

A Scientific Review Committee, which will be named at the Alliance Group Meeting in June 2012, will review applications and select award recipients.

For more information and instructions on how to submit an application, visit the Alliance web site at www.alliance-website.org or contact Denise Collins-Brennan at dcollinsbrennan@partners.org. The deadline for submission is January 2012.
Alliance Group Meeting
Plenary Session: The Genetic Basis for Cancer Therapeutics

William R. Sellers, MD
Vice President and Global Head of Oncology
Novartis Institute of Biomedical Research, Inc.

The Alliance for Clinical Trials in Oncology proudly presents noted researcher, Dr. William Sellers, as keynote speaker at the 2011 Alliance Group Meeting Plenary Session. Dr. Sellers’ research endeavors have focused on understanding genetic alterations in prostate cancer and elucidating the role of mutations in PTEN in deregulation of PI3K signaling.

At Novartis, Dr. Sellers oversees the small molecule and antibody-based drug discovery efforts conducted by research groups based in Cambridge, MA, Basel, Switzerland and Emeryville, CA.

To register for the meeting, please go to www.alliance-website.org

Alliance Member Web Site Now Available

All Alliance members now have access to the new secure Alliance Member area on the web site. The site was created to meet immediate member information needs, and contains information not available to the general public. It does not contain information specific to each legacy Group such as protocols and data forms, which are available on individual legacy web sites.

To access to the new web site, follow these simple steps:
• Log in to a browser and type the following URL: http://www.alliance-website.org to open the public Alliance web site.
• Click Alliance Member Login under the Navigation heading on the left side of the page.
• On the Member Login page, click the tab for your legacy Group.
• Enter the Username and Password you use to access your legacy web site.
• When your login is successful, you will see your Alliance account page.
• Click Member Information under the Navigation heading to view the Alliance Member site.

TIP: Before logging in to the Alliance Member web site, try logging in to your legacy member web site and resolve any current Username and/or Password problems.

If you need help accessing the new web site, contact your legacy Group by e-mail:
• ACOSOG – acosogweb@mc.duke.edu
• CALGB – calgb-support@calgb.duhs.duke.edu
• NCCTG – cancerroster@mayo.edu
Alliance Committee Chairs

Office of the Group Chair
Disease: Breast
Clifford Hudis, MD, Memorial Sloan-Kettering Cancer Center
Eric Winer, MD, Dana Farber Cancer Institute

Gastrointestinal
Alan Venook, MD, University of California at San Francisco
Genitourinary
Eric Small, MD, University of California at San Francisco
Leukemia
Richard Stone, MD, Dana-Farber Cancer Institute
Lymphoma
Bruce Cheson, MD, Georgetown University Medical Center
Myeloma
Paul Richardson, MD, Dana-Farber Cancer Institute
Neuro-Oncology
Evanthia Galanis, MD, Mayo Clinic
Respiratory
Everett Vokes, MD, University of Chicago

Modality: Clinical Research Professionals
Kandie Dempsey, MS, RN, Christiana Healthcare Services, Christiana Hospital

Oncology Nursing
Lisa Kottschade, MSN, RN, Mayo Clinic

Patient Advocate
Ellen Lavoie Smith, PhD, APRN, AOCN*, University of Michigan School of Nursing

Radiation Oncology
Jeffrey Bogart, MD, State University of New York Upstate Medical University

Transplant
Steven Devine, MD, The Ohio State University Medical Center

Administrative: Audit
Thomas Habermann, MD, Mayo Clinic
David Hurd, MD, Wake Forest University School of Medicine

Conflict of Interest
James D. Bearden, III, MD, Upstate Carolina CCOP
Jeffrey Crawford, MD, Duke University Medical Center

Constitution and Bylaws
Roscoe Morton, MD, Medical Oncology & Hematology Associates

Data and Safety Monitoring Board
Charles Rudin, MD, Johns Hopkins University

Ethics
Jeffrey Peppercorn, MD, Duke University Medical Center

Experimental Therapeutics
Charles Erlichman, MD, Mayo Clinic
Gary Schwartz, MD, Memorial Sloan-Kettering Cancer Center

Institutional Performance Evaluation
Ellis Levine, MD, Roswell Park Cancer Institute

Membership
Daniel Nikcevich, MD, Duluth Clinic CCOP

Patient Communication
Deborah Collyar

Pharmacy Committee
Darryl Grendahl, RPh, Mayo Clinic

Central Protocol Operations
Publications
Edith Perez, MD, Mayo Clinic

Study Concept Review
Monica Bertagnolli, MD, Dana-Farber/Brigham and Women's Cancer Center

Cancer Control Program
Cancer in the Elderly
Hyman Muss, MD, University of North Carolina at Chapel Hill
Harvey Cohen, MD, Duke University Medical Center

Community Oncology
Robert Behrens, MD, Iowa Oncology Research Association
Jeffrey Kirshner, MD, Hematology Oncology Associates of Central New York
Walter Peters, MD, Columbia Surgical Associates

Comparative Effectiveness Research
Deborah Schrag, MD, MPH, Dana-Farber Cancer Institute

Health Disparities
Electra Paskett, PhD, The Ohio State University Medical Center

Health Outcomes
Ethan Basch, MD, Memorial Sloan-Kettering Cancer Center
Jeffrey Sloan, MD, Mayo Clinic

Prevention
James Marshall, MD, Roswell Park Cancer Institute

Symptom Intervention
Charles Loprinzi, MD, Mayo Clinic

Translational Research Program
Imaging
Lawrence Schwartz, MD, Columbia University

Leukemia Correlative Sciences
Guido Marcucci, MD, The Ohio State University Medical Center

Pathology
Eric Hsi, MD, Cleveland Clinic

Pharmacogenomics and Population Pharmacology
Mark Ratain, MD, University of Chicago

American College of Surgeons Clinical Research Program
Member Services
Mitchell Posner, MD, University of Chicago

Education
Henry Kuerer, MD, PhD, MD Anderson Cancer Center

Cancer Care Standards Development
James Fleshman, MD, Washington University School of Medicine

Research and Development
Stephen Edge, MD, Roswell Park Cancer Institute
About Alliance for Clinical Trials in Oncology

The Alliance for Clinical Trials in Oncology is a newly formed cancer cooperative group funded by the National Cancer Institute. Created in 2011 by the merger of three legacy Groups (American College of Surgeons Oncology Group/ACOSOG, Cancer and Leukemia Group B/CALGB, and North Central Cancer Treatment Group/NCCTG), the Alliance is a single, integrated cooperative group that will develop and conduct more efficient clinical research studies, helping to bring clinical trial results to patients more quickly.

Our vision is to reduce the impact of cancer by uniting a broad community of scientists and clinicians from many disciplines that are committed to discovering, validating and disseminating effective strategies for the prevention and treatment of cancer.

Key Alliance research areas include, but are not limited to, breast, gastrointestinal, genitourinary, leukemia, lymphoma, myeloma, neuro-oncology, respiratory, transplant, experimental therapeutics, cancer control, and translational research. The preferred short name of the Group is “Alliance.”

Alliance Structure

The Alliance is comprised of the Office of the Group Chair and five programs (shown below), Executive Committee and Board of Directors.

**Office of the Group Chair**

<table>
<thead>
<tr>
<th>Leukemia</th>
<th>Lymphoma</th>
<th>Breast</th>
<th>Gastrointestinal</th>
<th>Genitourinary</th>
<th>Respiratory</th>
<th>Myeloma</th>
<th>Neuro-Oncology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advocates</td>
<td>Clinical Research Associates</td>
<td>Oncology Nursing</td>
<td>Radiation Oncology</td>
<td>Transplant</td>
<td>Experimental Therapeutics</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**STATISTICS AND DATA MANAGEMENT PROGRAM**

- CENTRAL PROTOCOL OPERATIONS PROGRAM
- TRANSLATIONAL RESEARCH PROGRAM
- CANCER CONTROL PROGRAM
- AMERICAN COLLEGE OF SURGEONS CLINICAL RESEARCH PROGRAM

**Statistics and Data Center**

- Protocol Office
- Integrated Biorepositories
- CCOP Research Base
- Commission on Cancer

**Biostatistics**

- Study Concept Review Committee
- Leukemia Correlative Sci
- Solid Tumor Correlative Sci
- Imaging

**Bioinformatics**

- Publications Committee
- Pharmacogenomics & Population Pharmacology
- Pathology
- Karyotype Review

**CONTACT US**

75 Francis Street
Boston, MA 02115
(617) 732-8919
info@alliance-website.org

To learn more about the Alliance, visit [www.alliance-website.org](http://www.alliance-website.org).